EyePoint Pharmaceuticals Inc (EYPT) Actualités

Form S-8 - Securities to be offered to employees in employee benefit plans

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company...

Form 8-K - Current report

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient...

Form 4 - Statement of changes in beneficial ownership of securities

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on...

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a...

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company...

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

WATERTOWN, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company...